Liquid diagnosis of hepatic encephalopathy : are we there already? by Machado, Mariana
Editorial
GE Port J Gastroenterol 2020;27:378–382
Liquid Diagnosis of Hepatic 
Encephalopathy: Are We There Already?
Mariana Verdelho Machado    
Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Received: May 24, 2020
Accepted: June 18, 2020
Published online: September 28, 2020
Mariana Verdelho Machado
Departmento de Medicina – Gastrenterologia e Hepatologia
Faculdade de Medicina, Universidade de Lisboa
Avenida Prof. Egas Moniz, PT–1649-028 Lisboa (Portulgal)
mverdelhomachado @ gmail.com
© 2020 Sociedade Portuguesa de Gastrenterologia 





Hepatic encephalopathy · S100β · NSE · Ammonia
Diagnóstico líquido de encefalopatia hepática – já 
uma realidade?
Palavras Chave
Encefalopatia hepática · S100β · NSE · Ammonia
Hepatic encephalopathy (HE) is a neurocognitive syn-
drome associated with liver disease and/or portosystemic 
shunts. Its diagnosis is clinical and requires exclusion of 
many other conditions that can present with similar neu-
ropsychiatric abnormalities [1]. The broad differential di-
agnosis, and huge clinical overlap with many metabolic, 
neurologic and psychiatric disorders, is a challenge for 
clinicians that must decide in which patients further lab-
oratorial, imaging and neurophysiological investigation 
is warranted. 
As opposed to overt HE (OHE), minimal HE (MHE) 
curses with no clinical manifestations, and is diagnosed 
on the bases of abnormal results on psychometric and 
neurophysiologic tests [1]. Those tests are quite sensitive 
but are time-consuming, require training and may be af-
fected by the patients’ age and education, explaining why 
MHE is the most under-diagnosed form of HE, even 
though it can afflict up to 80% of patients with chronic 
liver disease (CLD) [2]. The lack of recognition of MHE 
may have important implications, since MHE associates 
with impaired quality of life, decreased ability to perform 
daily tasks, and increased risk for work and traffic acci-
dents. Furthermore, MHE predicts the development of 
OHE and increased mortality [3]. 
Hepatologists’ work would be easier if there were a 
simple serum biomarker that could identify accurately 
patients with HE, either OHE in the emergency room, or 
MHE in the outpatient clinic. It would also help, if that 
biomarker would correlate with severity of HE in order to 
objectively monitor response to therapy. Monitoring of 
therapy response would be most useful in the context of 
MHE, since, in the case of OHE, once diagnosis is estab-
lished, clinical evaluation is more straightforward in as-
sessing evolution of HE severity. A biomarker must be 
accurate, reliable, sensitive/specific, and provide high 
predictive value.
Ammonia is a serum biomarker that 60–95% of clini-
cians use in their practice to diagnose HE [4], although 
studies show, that in the context of CLD, ammonia deter-
mination does not seem to change the management of the 
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patient, nor provides prognostic information [5]. Joint 
European and American guidelines state, however, that 
in a patient with OHE, a normal blood ammonia level 
should raise the suspicion of an alternative diagnosis [1]. 
Ammonia is an appealing candidate biomarker because 
of its role in the pathogenesis of HE. The first link be-
tween ammonia and HE was published in the work of 
Marcel Neucki and Ivan Pavlov in 1893, in portacaval-
shunted dogs with the so called “meat intoxication syn-
drome” [6]. More than 100 years after, ammonia is still 
placed in the centre of the pathogenesis of HE. Ammonia 
is mostly produced by the colonic microbiome from di-
etary proteins-derived nitrogen. Thereafter, 85% of am-
monia is detoxified through the Krebs cycle in the liver 
and excreted in the urine as urea, whereas 15% is metab-
olized in the muscle and brain through the synthesis of 
glutamine from glutamate. CLD is prone to hyperammo-
nemia, with colonic dysbiota increasing ammonia pro-
duction and decreased ammonia detoxification as a result 
of hepatocellular dysfunction, portosystemic shunts and 
sarcopenia. Hyperammonemia can be toxic to the central 
nervous system, promoting the development of HE. In 
the brain, detoxification of ammonia occurs in astrocytes, 
through glutamine synthetase with conversion of gluta-
mate to glutamine. Increased cellular glutamine has an 
osmotic effect, to which astrocytes respond realising os-
molytes such as myoinositol and taurine to the extracel-
lular space. This restores temporarily intracellular osmo-
larity, but increases susceptibility to subsequent cytotoxic 
cell edema. Neurons can uptake glutamine, being a pre-
cursor of excitatory glutamate and inhibitory 
γ-hydroxybutyric acid (GABA) neurotransmitters. In 
fact, hyperammonemia may induce cell death through 
excessive glutamate-induced N-methyl-D-aspartic acid 
(NMDA)-receptor activation, as well as an increased GA-
BAergic tone, transiently responsive to flumazenil [7]. 
Ammonia also impairs brain metabolism and promotes 
oxidative/nitrosative stress, promoting oxidation of RNA 
and proteins, which may explain multiple disturbances of 
neurotransmitter systems in HE. Albeit its role in the 
pathogenesis, ammonia is a poor biomarker for HE, in the 
context of CLD. More than 80% of cirrhotic patients with 
HE present elevated serum ammonia levels [8], however 
that also occurs in 30–60% of cirrhotic patients without 
HE [9]. Furthermore, correlations between ammonia lev-
el and severity of HE are only weak and inconsistent, with 
wide variation of levels, important overlap between 
grades of HE, and with no clear cut-off to discriminate 
severe HE [8]. Many factors can hamper the acuity of am-
monia for HE: technical aspects, individual susceptibility 
and environmental factors. Regarding technical aspects, 
the way blood is collected influences ammonia measure-
ment, and it should be avoided fist clenching and tourni-
quet use. Furthermore, the sample should be immediate-
ly placed on ice and centrifuged within 15 min of collec-
tion, since if left at room temperature ammonia 
concentration can increase 20% within 1 h and up to 
100% within 2 h. Ammonia levels are also influenced by 
the patient age, exercise and smoking. Many conditions 
can also increase ammonia such as urea cycle disorders, 
urinary tract infections from urease-producing microor-
ganisms, parenteral nutrition and some drugs such as val-
proic acid. Neurotoxicity of ammonia is also modulated 
by several factors such as muscle mass, kidney function, 
osmolarity, inflammation-induced increased blood-
brain barrier permeability, and genetic polymorphisms in 
enzymes of ammonia metabolism such as glutaminase 
gene [10].
A group in Valencia studied the toxic oxidant 3-nitro-
tyrosine as biomarker, the rationale being the known abil-
ity of hyperammonemia to induce oxidative stress. In 
fact, 3-nitro-tyrosine has been implicated as a toxin in-
volved in the pathogenesis of HE. Their pilot study did 
show promising results, with 3-nitro-tyrosine higher 
than 14 nM presenting almost 90% sensitivity, specificity, 
positive and negative predictive value for MHE [11]. Val-
idation from other groups is needed. 
Inflammation is another culprit in the pathogenesis of 
HE. In fact, circulating chemokines, cytokines, and am-
monia itself can activate microglia, the resident macro-
phage-like cells of the brain, promoting neuroinflamma-
tion, further impairing brain function. Small studies mea-
suring interleukin (IL)-18, and particularly IL-6 showed 
good correlations with the presence and severity of HE. 
IL-6 above 11 pg/mL seems a promising cut-off for MHE 
[12, 13].
Strebel et al. [14], in this issue of Portuguese Journal of 
Gastroenterology, studied 30 patients with liver cirrhosis, 
half with OHE and half with MHE, and evaluated two se-
rum biomarkers, S100β and neuron-specific enolase 
(NSE). They could not find a correlation with the sever-
ity of HE [14]. Furthermore, S100β and NSE levels did not 
change after treatment with L-ornithine and L-aspartate 
(LOLA), a probably efficient (albeit not routinely used) 
treatment for HE [15].
S100β is a 10.4 kDa calcium-binding protein that has 
a role in cellular signal transduction and calcium homeo-
stasis. In the brain, S100β is neurotrophic at the nanomo-
lar level and neurotoxic at the micromolar level [16]. It 
was named S100 after being detected, in 1965, in high 
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concentrations in brain factors from different mammals, 
and being soluble in 100% ammonium sulphate [17]. It is 
primarily synthesized in the brain by astrocytes, a target 
cell of hyperammonia neurotoxicity. S100β is not 100% 
brain-specific, since 10% is produced in other sources 
such as adipose tissue, skin and melanoma, as well as T-
lymphocytes [16]. Normal serum levels of S100β are be-
low 0.10 µg/L; it is metabolized and excreted by the kid-
ney and its expression does not seem to be influenced by 
ethnicity, gender or circadian rhythm, though it does 
seem to correlate with body mass index (BMI). S100β se-
rum levels increase in different neurologic disorders, that 
course with damage and activation of astrocytes. Indeed, 
S100β has been studied as a biomarker for different neu-
ropsychiatric diseases such as trauma- and cardiac arrest-
induced brain injury, ischemic stroke, sepsis-associated 
encephalopathy, epilepsy, schizophrenia, and Creutzfeldt-
Jakob disease [18–21]. The most validated conditions are 
trauma-induced brain injury and ischemic stroke, from 
which we can learn precious information regarding the 
kinetics of S100β elevation. After traumatic brain injury, 
there may be a peak at 3–6 h that correlates with mortal-
ity with high sensitivity; as such the Scandinavian guide-
lines recommend hospital discharge without CT-scan 
when S100β is normal at 6 h [18]. A second peak of S100β 
discriminates those patients with increased intracranial 
pressure and may help guide therapy [22]. After ischemic 
stroke, the peak in S100β is a little later, and the best time 
point in predicting outcome is 48–72 h [19]. Some pre-
liminary studies also studied the role of S100β as a bio-
marker in HE, particularly in the context of acute liver 
failure (ALF). In ALF, S100β increased up to 3 fold on 
admission and until 72 h; however, S100β levels did not 
correlate with the severity of HE, development of brain 
herniation or outcome [23–26]. Two small studies in 
CLD found normal S100β levels in patients without HE, 
and a 2-fold increase in patients with HE, suggesting that 
levels higher than 0.13 µg/L achieve 83% sensitivity and 
64% specificity for HE. S100β did not correlate with HE 
severity, being unable to discriminate OHE from MHE 
[16, 27].
NSE is an enzyme (2-phospho-D-glycerate hydroly-
ase) of the anaerobic glycolytic pathway, specific for neu-
rons and neuroendocrine cells. As such, it is a tumor 
marker for small cells lung cancer and neuroendocrine 
tumors. NSE is also used as a prognostic factor in brain 
damage after cardiac arrest, stroke, and trauma-induced 
brain injury [28, 29]. When measured in the 6 first hours 
post stroke, it has a strong positive correlation with in-
farct volume and negative with Glasgow coma scale. After 
cardiac arrest, NSE higher than 45 ng/mL at 48–72 h as-
sociates with worse neurological outcome, with a rate of 
Fig. 1. Landscape of the current candidate 
biomarkers for hepatic encephalopathy. 
HE, hepatic encephalopathy; MHE, mini-
mal hepatic encephalopathy, ALF, acute 
liver failure.
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false positive of only 5% [28]. NSE, as a biomarker of HE, 
has previously only been studied in the context of ACF, 
not in CLD. In pilot studies with ALF, NSE was not sig-
nificantly increased, though there was a trend to higher 
levels in patients who developed central herniation com-
pared to survivors [23, 26].
The study by Strebel et al. [14] comes out as a negative 
study; however, we must keep in mind some limitations 
of the study. First, it is a very small pilot study with less 
than 30 patients finishing the study. Second, it lacks two 
control groups: subjects without cirrhosis and patients 
with cirrhosis without HE. Third, there are some con-
cerns regarding the accurate diagnosis of HE, since only 
33% of the patients had increased ammonia level, either 
OHE or MHE, which is much lower than expected. As 
such, we cannot access how S100β and NSE perform as 
biomarkers for the diagnosis of HE. Having said that, 
two-third of patients presented increased levels of S100β 
(80% for patients with OHE), whereas only 1 out of 5 pre-
sented increased levels of NSE. The authors did not find 
a correlation between S100β/NSE and severity of HE; 
however, the West-Haven scale is subjective with high 
inter-observer and intra-observer variability, and psy-
chometric tests are affected by patient’s age and educa-
tion. The authors also did not find variations on S100β/
NSE after treatment with LOLA. Again, this result is dif-
ficult to interpret, since LOLA treatment did not associate 
with a decrease in ammonia, as it would be expected [15]. 
Lastly, biomarkers levels were not adjusted for confound-
ing variables, such as BMI, and the precipitating factors 
for HE that were excluded were not thoroughly described. 
It could also be a matter of timing of collection after the 
beginning of HE.
The present study, integrated in the previous litera-
ture, suggests that the role of S100β in the diagnosis of HE 
might be worthwhile further investigation, although it 
does not seem to be a good biomarker for grading HE and 
monitor therapy. NSE seems a much less promising can-
didate biomarker for HE in CLD, although it might have 
a role in evaluating patients with ALF too sick for liver 
transplantation (Fig. 1).
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